Testing ATHENA CAR-T for active lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests an experimental CAR-T cell therapy called ATHENA for people with lupus (SLE). It aims to see if the treatment can calm the immune system and reduce lupus activity when standard treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 56 years old.
- You must have been diagnosed with SLE (lupus) using the 2019 EULAR/ACR criteria and have positive blood tests for certain antibodies.
- Your lupus must be active (score of 8 or more on a disease activity scale) despite at least 6 months of standard treatment.
- You cannot have received CAR-T therapy, any gene therapy, or have had cancer before.
- You must not have severe kidney disease, active infections, or other autoimmune diseases needing treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment called rapcabtagene autoleucel for people with active lupus or lupus nephritis that hasn't improved with at least two standard therapies. It aims to reduce disease activity and may offer a new option for hard-to-treat cases.
This trial tests a new treatment called CAR-T cells, which are specially trained immune cells designed to target and destroy lupus-causing cells. It is for adults with active lupus that has not responded to at least two standard therapies.
This trial tests whether a type of immune cell therapy called CAR-T can help people with active lupus that hasn't responded well to standard treatments. It aims to reduce disease activity and improve symptoms.
This trial tests a new CAR-T cell treatment for people with lupus who still have moderate to severe symptoms despite trying standard medications. It aims to quickly stop the immune system from attacking the body.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.